Introduction
============

At present the global incidence of lung cancer is increasing with each passing year. Early diagnosis of lung cancer is critical for patients [@B1]. Clinically, there are instances of undiagnosed small solitary peribronchial pulmonary lesions located in segmental bronchi from 3th to 5th order with the lumen of 2-4 mm in diameter, because the diagnostic procedures for tissue biopsy are very difficult [@B2], [@B3]. Tissue cannot be easily reached by endobronchial biopsies (EBBX) due to the diameter of the patent bronchial lumen, while the other test of conventional diagnostic bronchoscopic procedures such as lavaging and brushing tend to obtain low positive cytological results. Furthermore, the endobronchial ultrasound guided transbronchial aspiration (EBUS-TBNA) cannot reach the lesions due to the large size of current convex probe of the EBUS bronchoscope with a 6.9 mm diameter. CT-guided percutaneous biopsies are associated with a higher risk of complications including pneumothorax or hemoptysis given the small lesions\' locations often near large blood vessels and the heart [@B4], [@B5]. Therefore, we performed this study to develop a more effective diagnostic method for solitary peribronchial pulmonary lesions located in segmental bronchi. In this study, 16 patients with solitary peribronchial pulmonary lesions located in the segmental bronchi from 3th to 5th order underwent R-EBUS assisted C-TBNA for pathological diagnosis [@B3]. The lesions were first located using R-EBUS to determine the target sites for puncture and then C-TBNA was performed to obtain cytologic and histologic specimens. A final pathological diagnosis was made based on the findings from the subsequent surgical specimens obtained by thoracic surgery. Finally, statistical analyses were performed for specimen results and complications. This study was conducted to evaluate the diagnostic accuracy and safety of the novel R-EBUS assisted C-TBNA technique in the diagnosis of solitary peribronchial pulmonary lesions located in the segmental bronchi.

1. Patients and Methods {#Section1}
=======================

1.1 Patients {#Section1.1}
------------

A retrospective analysis of bronchoscopic procedures was performed in the bronchoscopy suite of Changhai hospital between December 2014 and December 2015. During this period, 5085 bronchoscopic procedures were performed, among which 3376 were diagnostic. Out of the 3376 diagnostic bronchoscopies, R-EBUS was used to identify 188 lesions. Thirty of these 188 lesions were located in the segmental bronchi from the 3rd to 5th order. Based on the bronchoscopic findings, 16 out of these 30 lesions were in peribronchial with a patent endobronchial lumen. The distribution of these 16 lesions is shown in **Figure [1](#F1){ref-type="fig"}**. Therefore, in the present study these 16 patients (13 male and 3 female; mean age, 59.63 ± 11.10 years; age range, 33-77 years) underwent R-EBUS assisted C-TBNA for pathological diagnosis.

Inclusion criteria: Solitary peribronchial pulmonary lesions located in the segmental bronchi from 3th to 5th order were confirmed by CT. No mediastinal or hilar lymph node enlargement was found. Endobronchial lumens were patent by the detection of bronchoscopic findings as well as R-EBUS. Exclusion criteria: 1) severe cardiopulmonary dysfunction 2) coagulopathy 3) patients unable to tolerate bronchoscopic procedures. All the patients had signed informed consents, and this study was approved by the ethics committee of Changhai Hospital.

1.2 Methods {#Section1.2}
-----------

### 1.2.1 Preoperative Preparation {#Section1.2.1}

The patients were fasted for 8 hours and prohibited from drinking water for 4 hours before the examination. Pulmonary spiral CT scan, blood tests, and ECG were performed as routine examinations. Two bronchoscopists, who were proficient in C-TBNA and endobronchial ultrasound techniques, reviewed the chest CT before procedure to make sure the location of the solitary lesions.

### 1.2.2 Operation {#Section1.2.2}

As shown in Figure [2](#F2){ref-type="fig"}, the puncture process was divided into three steps: location, measurement and puncture.

The first step was to find the segmental bronchi with peribronchial lesion by R-EBUS, namely location. When operating, the bronchoscopist inserted the bronchoscope into the segmental bronchi closest to the lesion according to the CT scan. Then the R-EBUS probe was inserted into the segmental bronchi by the working channel of bronchoscope, the R-EBUS probe was operated and scanned with a 360-degree ring to obtain the complete ultrasonic image of peribronchial lesion, and all the bronchi in the target area were searched in turn. When the R-EBUS probe got the best ultrasounic image of the peribronchial lesion, the segmental bronchi with peribronchial lesion were recorded remembered.

Then, the distal end of bronchoscope was wedged in the nearest segmental bronchus of peribronchial lesion. The assistant was instructed to seize the body of bronchoscope at the level of nose or mouth to ensure bronchoscope not moving. The second step was to measure the size of lesion by R-EBUS, namely measurement. Because the diameter of the bronchial lumen was larger than the R-EBUS probe at the detection site, we used the R-EBUS probe to scan the bronchial wall clockwise until finding the peribronchial lesion. When the ultrasonic probe found the peribronchial lesion, the position and the angle of the ultrasonic probe is the exact endobronchial puncture position and the best puncture angle of the peribronchial lesion (action a). Then, the length (action b) and maximum diameter (action c) of the peribronchial lesion were measured by identifying the proximal, distal, and transverse margins utilizing the ultrasonic image. The R-EBUS probe was then withdrawn to measure the length between the proximal end of the lesion and the distal end of the bronchoscope (action d). The R-EBUS probe was subsequently withdrawn and the 19G WANG TBNA needle was inserted through the working channel of the bronchoscope. The TBNA guide-needle was extended from the distal end of the bronchoscope as determined by action d. The direction as well as the angle of the C-TBNA needle entering the lumen of the segmental bronchi should refer to action a. When the bronchoscopist confirmed that the C-TBNA needle had reached the optimal puncture position and angle, the assistant deployed the 19G WANG TBNA needle core, and the bronchoscopist performed needle aspiration biopsy of the peribronchial lesion by C-TBNA. Since the X-ray fluoroscopy was not used, the "jobbing technique" or "hub against the wall technique" was necessary to be used for bronchoscopist to avoid the failure of C-TBNA caused by the position movement of bronchoscope [@B6]. The angle of needle biopsy was according to action b and c. During the needle puncture and aspiration, where visual imaging with the bronchoscope was still available in the lumen of segmental bronchial. If the needle could not be penetrated through the bronchial wall, the needlepoint was probablely blocked by the crest of segmental bronchial. The bronchoscopist then readjusted the endobronchial position of C-TBNA needle to puncture again. If necessary, the TBNA needle was withdrawn and the ultrasonic probe reentered to scan the peribronchial lesion and determine the optimal endobronchial puncture site with angle, and then the C-TBNA was redone again. When the puncture needle successfully penetrated through the wall, the assistant then locked the puncture needle, it was connected to a 60 mL syringe for suction, and the bronchoscopist repeated a rapid jitter or pushed the needle back and forth for several times.

### 1.2.3 Specimen Processing {#Section1.2.3}

The bronchoscopist withdrew the needle with suction off, removed the whole needle assembly from the working channel of the scope and released the specimens from the tip of needle for liquid-based cytology, and histological specimens were removed and fixed in 10% formalin for histopathology. Some patients underwent endobronchial lavaging and brushing after the puncture, and the specimens were arranged for cytology and the detection of acid-resistant bacilli. Every peribronchial lesion underwent needle puncture 2-3 times.

### 1.2.4 Anaesthesia Method {#Section1.2.4}

All patients were evaluated by an anesthesiologist, and different anesthesia methods including local anesthesia and sedation were selected according to the patients\' status and wishes. We initially recommended moderate sedation, which was intravenous anesthesia combined with local anesthesia. Patients received oral nebulization of 10 mL 2% lidocaine injection for oropharyngeal anesthesia, as well as lidocaine gel for nasal anesthesia. Then, the open superficial venous micropump was used to pump an inductive dose of dexmedetomidine at the speed of 1 μg/kg. The pump was set up to be emptied in 10-15 min. Then, a maintenance dose was administered at the speed of 0.5-0.7 μg·kg^-1^·h^-1^. After the patient fell asleep, a maintainance dose of midazolam 0.03-0.05 mg/kg and fentanyl 25-50 μg were slowly administered during the procedure. If necessary, the nasopharyngeal airway tube was put to clear the upper respiratory tract. For patients with high risk for sedation such as uncontrolled hypertension and arrhythmia, only local anesthesia by means of oropharyngeal nebulization and nasal anesthesia were used.

### 1.2.5 Apparatus {#Section1.2.5}

All procedures were performed using an electronic flexible bronchoscope (Olympus 1T260 or Olympus 1TQ290, Olympus Medical Systems Co. Ltd, Tokyo, Japan), ultrasonic host (EV-ME1 universal ultrasonic endoscope image processing device, Olympus Medical Systems Co. Ltd., Tokyo, Japan), R-EBUS with a 1.7 mm diameter (UM-S20-20R, Olympus Medical Systems Co. Ltd., Tokyo, Japan), WANG™ transbronchial aspiration histology needles (MWF-319, ConMed Company, New York, USA), and a cell brush (Nanjing Micro-tech Medical Science and Technology Co., Ltd., Nanjing, China).

1.3 Statistical analysis {#Section1.3}
------------------------

SPSS version 16.0 (IBM SPSS Statistics, IBM Corporation, Armonk, New York, USA) was adopted to perform the statistical analyses. Quantitative values were expressed as‾x±SD and the statistical significance was determined by *t*-test. Numerical values were presented as percentages (%). *P* \< 0.05 was considered statistically significant.

2. Results {#Section2}
==========

2.1 Distribution and size of pulmonary lesions {#Section2.1}
----------------------------------------------

The patients\' demographic characteristics including the pulmonary lesion locations and sizes were shown in **Table [1](#T1){ref-type="table"}**. The mean diameter of these lesions was 19.28 ± 7.16 mm.

2.2 The anesthesia for patients {#Section2.2}
-------------------------------

In brief, sedation was performed to 11 patients with a mean age of 56.73 ± 9.40. Local anesthesia was performed to 5 patients with a mean age of 66.00 ± 12.92. R-EBUS assisted C-TBNA was successfully performed under both anesthesia methods. We analyzed the age of patients with different anesthesia methods and found that there was no statistically significant difference between two groups (*P* = 0.12).

2.3 Histopathologic and cytologic results of C-TBNA {#Section2.3}
---------------------------------------------------

C-TBNA was performed for all the 16 patients, and the pathological results were shown in **Table [1](#T1){ref-type="table"}**. C-TBNA histopathological evaluation of the 16 tissue specimens showed that 14 cases were malignant, including 8 adenocarcinomas, 4 squamous cell carcinomas, and 2 small cell carcinomas, and the remaining 2 were non-malignant disease. With respect to cytologic results of C-TBNA, 14 were malignant, and the remaining 2 were non-malignant. Combining both results, 15 were malignant, including 9 adenocarcinomas (56.25%), 4 squamous cell carcinomas (25.00%), and 2 small cell carcinomas (12.50%), 1 was non-malignant (6.25%) and the patient had no clinical follow-up.

2.4 Accuracy of different procedures {#Section2.4}
------------------------------------

According to the patients\' states after C-TBNA, some of patients underwent endobronchial bronchoscopic washing and brushing for cytological test; lavaging was performed for 10 patients with all negative results. Brushing was performed for 10 patients, malignant cell were found only in 4 out of 10. However, C-TBNA was performed for all 16 patients, and 15 of these were malignant. Comparing to the result of final surgical pathology, the diagnostic accuracy rate, sensitivity and missed diagnosis rate of the cytological results of washing were 0, 0 and 100%, respectively. The diagnostic accuracy rate, sensitivity and missed diagnosis rate of the cytological the results of brushing were 40%, 40% and 60%. However, the accuracy rate, sensitivity and missed diagnosis rate of histopathological results of C-TBNA, were 87.5%, 87.5% and 12.5%, respectively. The diagnostic accuracy rate, sensitivity and missed diagnosis rate of C-TBNA cytological results were 87.5%, 87.5% and 12.5%, respectively. Upon combining both results above, the total diagnostic accuracy rate, sensitivity and missed diagnosis rate were 93.75%, 93.75% and 6.25%, respectively (**Table [2](#T2){ref-type="table"}**).

2.5 Complications {#Section2.5}
-----------------

There were no occurrences of pneumothorax, mediastinal emphysema, or mediastinal hemorrhage in any patient. Only 2 patients had complications of \>5 mL bleeding after needle puncture, but the bleeding was controlled quickly with bronchoscopic management of bronchoscopic wedge technique and endobronchial ice-saline injection.

3. Typical cases {#Section3}
================

A 55-year-old male patient presented with symptoms of hemoptysis for 10 days. CT confirmed a peribronchial lesion with 11 × 8 × 9 mm in size and located in the lingular lobe of Left upper lobe (**Figure [3](#F3){ref-type="fig"}a**). Initial bronchoscopic airway exam was normal (**Figure [3](#F3){ref-type="fig"}b**), and the lumen of segmental bronchi was patent. The endobronchial lavaging and brushing were performed and both cytological results were negative. Then the second diagnostic bronchoscopic procedures with R-EBUS assisted C-TBNA was performed 2 days later. R-EBUS was used to reach a peribronchial lesion in the orifice B5 segment of LUL. The ultrasonic imaging from radial probe showed a peribronchial solid nodule with continuous clear edge, and 11 mm in the maximum diameter (**Figure [3](#F3){ref-type="fig"}c**). After the needle puncture site with angle was confirmed by R-EBUS, the radial probe was pulled out, then the TBNA needle with 19G in size was inserted through the working channel of the bronchoscope. The "jabbing technique" of C-TBNA needle puncture was performed according to the initial evaluation of R-EBUS (**Figure [3](#F3){ref-type="fig"}d**). Satisfactory specimens were obtained, and the histopathological results of C-TBNA showed adenocarcinoma (**Figure [3](#F3){ref-type="fig"}e**). The non-small cell cancer cells were found in the cytological results of C-TBNA (**Figure [3](#F3){ref-type="fig"}f**). The patient underwent thoracic surgery 5 days later. It was confirmed that pathology of the surgical specimen was consistent with the result of C-TBNA. The final diagnosis of low-differentiated primary adenocarcinoma of LUL was confirmed by immunohistochemical result subsequently.

4. Discussion {#Section4}
=============

In 1949, Transbronchial needle aspiration, C-TBNA was first proposed by Dr. Eduardo Schieppati in Argentina in diagnosing mediastinal lymph nodes of the central airway by the rigid bronchoscope [@B7]. Then, in 1978, Ko-Pen Wang in the United States improved the method [@B8] then C-TBNA could be performed by flexible bronchoscope. Wang not only drew the "Wang\'s TBNA map", systemically described the puncturing methods of mediastinal and hilar lymph nodes [@B9] and designed a series of C-TBNA needles [@B10], [@B11], but also focused on the development and clinical application of C-TBNA puncture techniques. Owing to this, the C-TBNA technique had been the standard method of diagnosis of mediastinal and hilar lymph nodes in the central airway for over 20 years. For an experienced bronchoscopist, the diagnostic yield of mediastinal and hilar lymph nodes by C-TBNA was between 96-100% [@B12], while the diagnostic yield of fluoroscopy assisted transbronchial biopsy (TBBX) and C-TBNA could fluctuate between 48% and 69% in the diagnosis of pulmonary peripheral lesions (PPLs) [@B13]-[@B15]. C-TBNA became one of the key technologies in diagnostic bronchoscopies. However, with the development of bronchial ultrasonic technologies, especially after 2004, following clinical promotion of a new type of convex probe endotracheal ultrasonic bronchoscope (CP-EBUS), EBUS-TBNA was accepted by clinicians as a safe and efficient technique for mediastinal and hilar lymphadenopathy gradually. At present, the sensitivity and specificity of EBUS-TBNA could reach 89.89% and 72.73% respectively in the pathological diagnosis of mediastinal and hilar lymph nodes [@B16]-[@B18]. EBUS-TBNA has expanded the role of C-TBNA in the staging and diagnosis of lung cancer. With the rise of modern navigation technologies, the exploration rate of PPLs can also reach 80-90% [@B2]. C-TBNA, therefore, was considered to be an essential technology in both the central airway and in pulmonary peripheral lesions [@B19].

In the present study, all the 16 peribronchial lesions were located in the segmental bronchi from 3rd to 5th order, where the patent lumen of segmental bronchi was 2-4 mm in diameter. Any technique of endobronchial forceps biopsy, including EBUS-GS was not able to reach the peribronchial lesions, while the EBUS-TBNA scope could not get into the lumen of the fourth bronchus due to the large size of convex probe either. Therefore, C-TBNA has become the only effective diagnostic method to obtain pathological tissue samples. However, there is no "map" available for the peribronchial lesions located in the segmental bronchi, which is different from the fixed distribution of the mediastinal and hilar lymph nodes of the central airway [@B9], and the endobronchial puncture site of C-TBNA may be very difficult to identify according to the chest CT imaging, even for experienced bronchoscopists. Therefore, we first used R-EBUS to scan the bronchi to find the peribronchial lesion depending on the chest CT imaging. After the solid peribronchial lesion and the peripheral blood vessels were located, the best angle, location, and depth of the needle puncture were determined by the R-EBUS. Then the C-TBNA procedure using a 19G WANG TBNA needle was performed. As the diameter of proximal endobronchial lumen was more than 4 mm widely, there was enough space to visually adjust the angle of C-TBNA needle, so that the needle could be advanced to the ideal puncture position with subsequent performance of the conventional method of C-TBNA [@B6]. The diagnostic yield could be enhanced by the combined techniques with C-TBNA assisted R-EBUS according to our study.

This study also suggested that the current R-EBUS needed to be improved in probing the depth of the peribronchial pulmonary lesions. Further, there was no doppler function equipped with the present ultrasonic radial probe, so it was not effective in distinguishing the peripheral blood vessels closed to the lesion, and this also caused bleeding complications during the needle puncture. In addition, for a peribronchial lesion located in the upper lobe, the C-TBNA procedure using 19G tissue needle combined with a therapeutic bronchoscope sometimes could not be implemented effectively due to limited bending angle of therapeutic bronchoscopic insertion part. Therefore, it is necessary to develop equipment for increasing the diagnostic yield in the future. Fortunately, updated C-TBNA techniques as well as new types of puncture needles for different puncture sites are now available, which have promoted renewal of C-TBNA [@B20], [@B21]. In addition, new advanced navigation systems, such as virtual bronchoscopic navigation (VBN) system could be used to evaluate the peribronchial lesions, guide the needle puncture site, angle and depth, as well as reconstruct the large blood vessels around bronchi, and the VBN system offers a more comprehensive and three-dimensional identification, especially in the adjacent relationship between peripheral blood vessels surrounding the lesion as well as the important organs. This helps the C-TBNA to be a safe and efficient method to further improve the diagnostic yield and reduce the complications of bleeding [@B22]-[@B24] (**Figure [4](#F4){ref-type="fig"}**).

Similar to our present study, Hanaoka et al. [@B25] used VBN-assisted C-TBNA in the diagnosis of smaller peribronchial lesions with average size of 11.47 ± 3.4 mm. C-TBNA was used for obtaining the specimens for all the 15 cases. However, different from our research, C-TBNA needle with 21 G in size was used for the needle aspiration, and the C-TBNA needle was guided to reach the lesion via X-ray fluoroscopy, which could be used to perform the C-TBNA biopsy for smaller lesions located in more distal airways. The diagnostic yield could reach 70% with fewer bleeding complications during the puncture. Both investigations showed the value of C-TBNA technology in diagnosing peribronchial pulmonary lesions located in the segmental bronchi.

Undeniably, there were limitations in the present study. Not all the patients underwent contrast chest CT scan before the endobronchial procedures, which resulted in the occurrence of bleeding complication in 2 patients. In addition, all procedures were performed by two experienced bronchoscopists. The data is retrospective and limited. Most cases were malignant, and one negative case was not clinically followed up. Therefore, future research on prospective, large-sample data is required.

In recent years, more and more studies have shown the value of C-TBNA in needle aspiration biopsy of the peripheral pulmonary lesions (PPLs) farther from the central airway. Sasada et al. [@B26] diagnosed PPLs through EBUS-GS-TBNA. A 21G needle was used to obtain specimens through the EBUS-GS. The results showed that there was no statistical difference in the diagnosis yield of the "within" PPLs or "outside" lesions with the guided sheath (GS)-TBNA needle aspiration biopsy [@B27]. By comparing the diagnostic yield of GS-TBNA, transbronchial catheter aspiration (TBCA) and TBBX in the PPLs, Franke et al. [@B28] found that GS-TBNA had a higher diagnostic yield for malignant PPLs, and its diagnostic yield was about twice that of TBBX in combination with the result of TBCA. A recent meta-analysis of 18 clinical studies showed that C-TBNA was significantly better than TBBX in the diagnosis of PPLs [@B29]. The results of AQuIRE of the multi-center prospective study of Ost et al. pointed out that for PPLs, the new navigation technology did not achieve the high diagnostic yield, however, C-TBNA was a key technique to improve the diagnostic yield of PPLs [@B30]-[@B32]. Nevertheless, the application of C-TBNA still faces many challenges in the diagnosis of peribronchial lesions. For example, it is very difficult to adjust the puncture angle of the needle due to the limited diameter of the smaller peripheral airway lumen. In addition, there are no standard methods currently recommended for the procedure of PPLs needle aspiration biopsy. Furthermore, PPLs with ground glass opacity (GGO) in CT imaging may not be easily appreciated by X-ray fluoroscopy and operators still face the problem of excessive radiation exposure when X-ray are used. Fortunately, bronchoscopists\' have been able to effectively locate and biopsy the GGO PPLs even with less radiographic exposure with the help of new navigation techniques such as Conebeam CT [@B33], [@B34]. Furthermore, new TBNA needle and puncture methods for PPLs are also being developed in recent years [@B35]. Regarding fine needle biopsy under CT guidance the needle is definitely larger 18G and higher, however; the complication of pneumothorax is more often. The specimen also is all the time tissue compared to needles of ≤ 25G which are often used for technical reasons with endoscopic techniques. Several times it is up to the setting of each hospital/institution expertise and equipment to decide for each patient what is the appropriate method of biopsy.

Taken together, C-TBNA still exists as a core diagnostic bronchoscopic technique, which will have great application in prospect. With the development of new technology, use of transbronchial needle aspiration will steadily advance from the central airway to the PPLs to improve the diagnostic yield, simplify the biopsy method, and improve the overall safety of the procedure. Therefore, the fundamental C-TBNA training still needs to be strengthened.
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![**The distribution of all the solitary peribronchial pulmonary lesions.** As shown above the distribution of all the 16 solitary peribronchial pulmonary lesions is: 3 lesions were present in the RUL, 1 lesion was in the RML, 1 lesion was in the RLL(S), 3 lesions were in the RLL(B), 1 lesion was in the LUL, 1 lesion was in the LUL(L), 1 lesion was in the LLL(S), and 5 lesions were in the LLL(B). The numbers in the figure followed the sequence of patients\' enrollment. (RUL=right upper lobe, RML=right middle lobe, RLL(S) =superior segment of right low lobe, RLL(B)=basal segment of right low lobe, LUL=left upper lobe, LUL(L)=lingular segment of left upper lobe, LLL(S)=superior segment of left low lobe, LLL(B)=basal segment of left low lobe.)](jcav10p0634g001){#F1}

![**The puncture process with R-EBUS assisted C-TBNA for solitary peribronchial lesion in the segmental bronchi.** The puncture process was divided into 3 steps with location, measurement and puncture in sequence, the breakdown of each step was detailed as shown.](jcav10p0634g002){#F2}

![**R-EBUS assisted C-TBNA in the diagnosis of a peribronchial pulmonary nodule located in the segmental bronchi of LUL.** (a) A solid pulmonary nodule located in the lingular lobe of LUL. (b) Initial bronchoscopic airway exam was normal, the lumen of the segment B5 of LUL was patent. (c) The ultrasonic imaging from radial probe showed a solid peribronchial nodule with continuous clear edge, and 11 mm in the maximum diameter. (d) The C-TBNA was performed using MW-319 WANG\'s needle according to the initial evaluation with puncture site and angle obtained by R-EBUS probe. (e) The HE staining of C-TBNA specimen showed typical adenocarcinoma. (f) Malignant cell, suspicious non-small cell lung cancer was found by the cytological result of C-TBNA.](jcav10p0634g003){#F3}

![**3D anatomical schematic diagram of a peribronchial pulmonary lesion with surrounding structures reconstructed by the VBN system.** (a) 3D anatomical schematic diagram reconstructed by the VBN system showed a peribronchial lesion located in the lingular lobe of left upper lobe, the tracheobronchial tree with surrounding large blood vessels. The green mark within the yellow circle showed the lesion (Lung Point® AR Bronchoscopic Navigation, Broncus Medical, Inc.). (b) The lesion could be easily recognized by the fluoroscopy with the help of combination imaging of 3D anatomical schematic diagram and coronary chest CT imaging. (c) The endobronchial location of the solitary peribronchial lesion was seen with the VBN bronchoscopy. (d) During bronchoscopic airway exam, the corresponding position of the peribronchial lesion was marked realtimely to assist the C-TBNA procedure to efficiently obtain the pathological tissue. The final cytological results showed no malignant findings. After 1 year follow-up, the lesion in the left upper lobe shrinked obviously.](jcav10p0634g004){#F4}

###### 

Demographics of patients with solitary peribronchial pulmonary lesions

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case no.   Age/\   Peribronchial Lesion location   Lesion diameter (mm)   C-TBNA pathology                     C-TBNA cytopathology               Airway washing   Airway Brushing                    Surgical pathology
             Sex                                                                                                                                                                                        
  ---------- ------- ------------------------------- ---------------------- ------------------------------------ ---------------------------------- ---------------- ---------------------------------- ---------------------------------
  1          55/M    LUL.B^5^                        11×8×9                 adenocarcinoma                       malignant cell, suspicious NSCLC   negative         negative                           primary adenocarcinoma

  2          47/M    RLL.B^8^                        17.9×15.8×16           suspicious adenocarcinoma            malignant cell, suspicious NSCLC   negative         malignant cell, suspicious NSCLC   primary adenocarcinoma

  3          45/M    RUL.B^3^                        29.4×27×34.5           suspicious small cell carcinoma      malignant cell, suspicious SCLC    ---              ---                                small cell carcinoma

  4          61/F    LLL.B^9^                        13.2×15×16.9           suspicious adenocarcinoma            malignant cell, suspicious NSCLC   negative         ---                                adenocarcinoma

  5          63/M    RUL.B^3^                        14.7×13.2×16.5         small cell carcinoma                 malignant cell, suspicious SCLC    negative         negative                           small cell carcinoma

  6          63/M    LLL.B^9^ b                      10×15.1×13             adenocarcinoma                       malignant cell, suspicious NSCLC   negative         negative                           primary adenocarcinoma

  7          77/M    RLL.B^6^                        25.3×23×19             suspicious squamous cell carcinoma   squamous cell carcinoma            negative         negative                           squamous cell carcinoma

  8          60/M    RLL.B^7^                        15.6×12×13             suspicious adenocarcinoma            malignant cell, suspicious NSCLC   negative         adenocarcinoma cell                primary adenocarcinoma

  9          62/M    RUL.B^2^a                       17.5×16.9×15           squamous cell carcinoma              squamous carcinoma cell            negative         negative                           primary squamous cell carcinoma

  10         63/M    LLL.B^9^                        14×12×15.5             suspicious adenocarcinoma            malignant cell, suspicious NSCLC   negative         negative                           primary adenocarcinoma

  11         75/M    LLL.B^6^c                       30×26×35               suspicious squamous cell carcinoma   negative                           negative         squamous carcinoma cell            primary squamous cell carcinoma

  12         54/M    LLL.B^10^                       21.3×17×15             adenocarcinoma                       malignant cell, suspicious NSCLC   ---              adenocarcinoma cell                primary adenocarcinoma

  13         70/M    RML.B^4^                        7×12.8×9               suspicious\                          malignant cell, suspicious NSCLC   ---              ---                                primary adenocarcinoma
                                                                            adenocarcinoma                                                                                                              

  14         33/F    RLL.B^9+10^                     21.4×17×19             suspicious squamous carcinoma cell   squamous carcinoma cell            ---              ---                                primary squamous cell carcinoma

  15         62/F    LLL.B^9^                        16.5×15×21.1           non-malignant disease                malignant cell, suspicious NSCLC   ---              ---                                primary adenocarcinoma

  16         64/M    LUL.B^1^                        11×8×9                 non-malignant disease                negative                           ---              ---                                no clinical follow-up
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

M=male, F=female, RUL=right upper lobe, RML=right middle lobe, RLL=right low lobe, LUL=left upper lobe, B=bronchus, NSCLC=non-small cell lung cancer, SCLC=small cell lung cancer, LLL=left low lobe, C-TBNA=conventional transbronchial needle aspiration.

###### 

Analysis of the results of different diagnostic procedures

  ------------------------------------------------------------------------------------------------------
  Procedure                                  Accuracy rate (%)   Sensitivity\   missed diagnosis rate\
                                                                 (%)            (%)
  ------------------------------------------ ------------------- -------------- ------------------------
  Histopathological results\                 87.5%               87.5%          12.5%
  of C-TBNA (n = 16)                                                            

  Cytological results of C-TBNA (n = 16)     87.5%               87.5%          12.5%

  Cytological results of brushing (n = 10)   40%                 40%            60%

  Cytological results of washing (n = 10)    0                   0              100%
  ------------------------------------------------------------------------------------------------------
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